

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司\***  
(Incorporated in the Cayman Islands with limited liability)  
(Stock code: 1548)

**INSIDE INFORMATION**  
**ACHIEVING MAJOR MILESTONE IN THE COLLABORATION**  
**WITH JANSSEN BIOTECH, INC.**

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (a) the inside information announcement of the Company dated 22 December 2017 in relation to the collaboration and license agreement (the “**Agreement**”) entered into among (i) Legend Biotech USA Inc., a non-wholly-owned subsidiary of the Company (“**Legend U.S.**”), (ii) Legend Biotech Ireland Limited, a non-wholly-owned subsidiary of the Company (“**Legend Ireland**”, together with Legend U.S., “**Legend**”), and (iii) Janssen Biotech, Inc. (“**Janssen**”), (b) the inside information announcement of the Company dated 17 December 2018 on the achievement of the first milestone relating to the clinical trial in the US and Legend’s entitlement to a milestone payment in the amount of US\$25,000,000 payable by Janssen, and (c) the inside information announcement of the Company dated 28 July 2019 on the achievement of the second and third milestones relating to the clinical trial in the US and Legend’s entitlement to a milestone payment in the amount of US\$30,000,000 and US\$25,000,000 payable by Janssen, respectively (collectively, the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

The Board is pleased to announce that, according to the terms and conditions of the Agreement, the fourth milestone relating to the US clinical development of the B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, LCAR-B38M (JNJ-68284528 (JNJ-4528)), has been achieved and Legend is entitled to a milestone payment in the amount of US\$30,000,000 payable by Janssen for the fourth milestone.

To the best knowledge and belief of the Company, Janssen and its ultimate beneficial owners are third parties independent of the Company. The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise in caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 28 January 2020

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.*

*\* For identification purposes only*